First Quadrant LP Upped Abbvie (ABBV) Holding; Shorts at Tesaro (TSRO) Lowered By 4.02%

February 15, 2018 - By Henry Gaston

Tesaro Incorporated (NASDAQ:TSRO) had a decrease of 4.02% in short interest. TSRO’s SI was 7.42M shares in February as released by FINRA. Its down 4.02% from 7.73M shares previously. With 871,000 avg volume, 9 days are for Tesaro Incorporated (NASDAQ:TSRO)’s short sellers to cover TSRO’s short positions. The SI to Tesaro Incorporated’s float is 19.92%. The stock decreased 0.31% or $0.19 during the last trading session, reaching $61.47. About 192,645 shares traded. Tesaro, Inc. (NASDAQ:TSRO) has risen 254.28% since February 15, 2017 and is uptrending. It has outperformed by 237.58% the S&P500.

First Quadrant LP increased Abbvie Inc (ABBV) stake by 302.05% reported in 2017Q3 SEC filing. First Quadrant LP acquired 138,042 shares as Abbvie Inc (ABBV)’s stock rose 6.17%. The First Quadrant LP holds 183,743 shares with $16.33 million value, up from 45,701 last quarter. Abbvie Inc now has $179.89 billion valuation. The stock decreased 0.35% or $0.4 during the last trading session, reaching $112.68. About 1.56M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 15, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It worsened, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Gideon Capital Advisors Inc owns 0.39% invested in AbbVie Inc. (NYSE:ABBV) for 4,473 shares. Kbc Group Incorporated Nv owns 1.07% invested in AbbVie Inc. (NYSE:ABBV) for 1.33 million shares. Cadinha & Co Limited Liability Co has invested 0.36% in AbbVie Inc. (NYSE:ABBV). Diversified Trust owns 12,591 shares. Natixis holds 295,732 shares. Thompson Siegel Walmsley Limited Liability Corp holds 58,290 shares or 0.06% of its portfolio. Barometer Cap reported 1.79% stake. Jacobs & Com Ca reported 1.27% in AbbVie Inc. (NYSE:ABBV). Pioneer Commercial Bank N A Or holds 2.32% in AbbVie Inc. (NYSE:ABBV) or 50,395 shares. Advent Capital Mgmt De holds 5,000 shares. First Long Island Ltd Limited Liability Company has 2.49% invested in AbbVie Inc. (NYSE:ABBV). Stone Run Cap Limited Liability, a New York-based fund reported 4,300 shares. Financial Advisory invested in 3,391 shares. Blue Financial Cap holds 0.81% or 14,964 shares. Amalgamated Fincl Bank has invested 0.53% of its portfolio in AbbVie Inc. (NYSE:ABBV).

First Quadrant LP decreased Landauer Inc (NYSE:LDR) stake by 11,367 shares to 3,745 valued at $252,000 in 2017Q3. It also reduced Voya Financial Inc (NYSE:VOYA) stake by 96,029 shares and now owns 65,580 shares. Norfolk Southern Corp (NYSE:NSC) was reduced too.

Since September 11, 2017, it had 0 insider purchases, and 5 selling transactions for $25.59 million activity. 6,699 AbbVie Inc. (NYSE:ABBV) shares with value of $589,512 were sold by Michael Robert A.. The insider Schumacher Laura J sold 145,510 shares worth $14.07 million. RICHMOND TIMOTHY J. also sold $8.57 million worth of AbbVie Inc. (NYSE:ABBV) on Monday, December 18. SALEKI-GERHARDT AZITA sold $705,655 worth of stock. Another trade for 18,300 shares valued at $1.66 million was made by Gosebruch Henry O on Monday, October 30.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Monday, January 29 by Credit Suisse. The stock has “Buy” rating by Leerink Swann on Tuesday, December 5. As per Thursday, November 16, the company rating was maintained by BMO Capital Markets. As per Friday, February 2, the company rating was maintained by Argus Research. The rating was maintained by Jefferies with “Buy” on Tuesday, January 16. The stock has “Hold” rating by Credit Suisse on Thursday, July 20. The rating was upgraded by Citigroup to “Buy” on Tuesday, February 23. The rating was maintained by BMO Capital Markets on Wednesday, October 11 with “Hold”. SunTrust initiated the shares of ABBV in report on Wednesday, July 22 with “Buy” rating. The rating was maintained by Jefferies on Thursday, May 25 with “Buy”.

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.25, from 1.46 in 2017Q2. It turned negative, as 47 investors sold Tesaro, Inc. shares while 65 reduced holdings. 44 funds opened positions while 91 raised stakes. 58.28 million shares or 5.16% more from 55.42 million shares in 2017Q2 were reported. Strs Ohio owns 492 shares for 0% of their portfolio. Ubs Asset Management Americas has 0.04% invested in Tesaro, Inc. (NASDAQ:TSRO) for 299,397 shares. Sivik Global Health Limited Liability Company accumulated 0.44% or 10,000 shares. Amer Century Cos holds 0% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO) for 5,826 shares. Credit Agricole S A reported 26,297 shares. Goldman Sachs Group has 0.01% invested in Tesaro, Inc. (NASDAQ:TSRO). Wellington Gru Llp has 6.61 million shares for 0.2% of their portfolio. Iguana Health Mngmt Ltd Liability Company accumulated 25,000 shares. Nationwide Fund Advisors holds 0.03% or 61,500 shares in its portfolio. Greenwood Assoc Ltd Liability Corporation stated it has 0.09% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO). Columbia Partners L L C Investment Mngmt holds 0.19% or 11,096 shares in its portfolio. 700 were accumulated by Livforsakringsbolaget Skandia Omsesidigt. Parametric Port Assocs Limited Company has 0% invested in Tesaro, Inc. (NASDAQ:TSRO). First Advisors L P holds 0.02% or 58,952 shares. 3,513 were reported by Dupont Capital.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $3.34 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: